Sir,

A 36-year-old lady presented to the A&E with a 2-day history of generalized, severe progressive weakness of her limbs. Two days prior to her presentation, she had been exercising vigorously at the gym and subsequently developed muscle pain. In the hours following, she developed progressive weakness in her upper and lower limbs. She became unable to walk or stand. She described several previous episodes of leg weakness and numbness, especially at night, over a few months. On further questioning, she stated that she had been taking up to eight tablets of an ibuprofen codeine combination (200 mg + 12.8 mg respectively) everyday for 3 months for backache. She had been admitted previously with profound iron deficiency anaemia and weakness but mild hypokalaemia 19 months before, which had resolved completely with oral supplementation. There was no other relevant family or drug history. On examination, the patient was dehydrated, afebrile (37.4°C), with a regular pulse rate of 90 bpm and blood pressure 123/83 mmHg. She had decreased power in all four limbs (MRC score of 3/5 in the lower limbs and 4/5 in the upper limbs). Blood tests on admission showed a serum potassium of 1.7 mmol/L and a high serum creatinine level of 282 mmol/L and urea 12.8 mmol/L (sodium 130 mmol/L, chloride 95 mmol/L, creatinine kinase 289 i.u./mL). Arterial blood gas sampling revealed a metabolic acidosis (pH 7.20, pCO~2~ 3.04 kPa (23 mmHg), pO~2~ 15.7 kPa (118 mmHg), HCO~3~ 11.0 mmol/L, base deficit 18) with an anion gap of 25 mmol/L. Serum lactate was normal (0.9 mmol/L) and salicylate was undetected. An *E. coli* UTI was discovered and treated. ECG changes were consistent with severe hypokalaemia. Her urine sodium at presentation was 42 mmol/L, potassium 12.4 mmol/L, urea 27 mmol/L and osmolality of 134 mOsm/kg. The urine osmolal gap was −1.8, making recent toluene abuse unlikely. Immunological tests were negative (inter alia, Hep 2 cells, ANA, and autoimmune profile negative). Subsequent investigations showed transient polyuria (urine volume up to 4.3 L/day), high 24-h urinary K^+^ wasting (175 mmol/day). CT scan of the abdomen showed marked bilateral nephrocalcinosis, but no other abnormalities.

The patient re-presented to the emergency department with similar symptoms a month later. On this occasion, she was also found to be hypokalaemic (2.1 mmol/L) with hyperchloraemic metabolic acidosis (pH 7.23, HCO~3~ 14.7 mmol/L, base deficit 12.6). Her serum anion gap was normal (13 mmol/L). Whilst acidotic, her urine anion gap was + 7 mmol/L and urine pH 6.52. She was again treated with fluid resuscitation and potassium repletion. She denied further NSAID or diuretic use. In view of the recurrent hypokalaemia, advanced nephrocalcinosis, urine pH, positive urine anion gap and normal anion gap metabolic acidosis, a diagnosis of longstanding type 1 RTA was made. She made a full recovery and was discharged 5 days later on potassium citrate supplementation, and remained potassium replete on follow-up.

There have been reports of ibuprofen codeine combination, particularly in excess doses, causing acute and transient RTA \[[@R1]\]; when characterized it has been reported to be type 2. Our patient now meets criteria for a diagnosis of type 1 RTA. This pre-existing condition was not diagnosed until her admission with life-threatening hypokalaemia, after taking an ibuprofen codeine combination for 3 months. This presentation with far graver hypokalaemia than before was accompanied by no alternative explanation for the development of 0.76 mol potassium deficit, and was associated with transient hypophosphataemia. We speculate that at the time of presentation she had developed a proximal tubulopathy, attributable to the ibuprofen codeine combination, resulting in a combined renal tubular acidosis with dramatic consequences. Vigilance in eliciting a detailed analgesic history remains important in patients with acute acidoses, especially in patients with pre-existing renal conditions.
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